Related references
Note: Only part of the references are listed.Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies
James Cassidy et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2009)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer
Alberto Sobrero et al.
ONCOLOGY (2009)
Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients
Markus Moehler et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients A Meta-analysis
Shobha Rani Nalluri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study
Howard S. Hochster et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
Axel Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
J. Tol et al.
ANNALS OF ONCOLOGY (2008)
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
Frank A. Scappaticci et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with, metastastic colorectal cancer
J. A. Meyerhardt et al.
ANNALS OF ONCOLOGY (2007)
A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB
H. L. Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gastrointestinal perforation due to bevacizumab in colorectal cancer
Muhammad Wasif Saif et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Infectious complications of monoclonal antibodies used in cancer therapy - A systematic review of the evidence from randomized controlled trials
Petros I. Rafailidis et al.
CANCER (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: A single-institute study
Arvinder Bir et al.
ONCOLOGY (2007)
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200
B. J. Giantonio et al.
ANNALS OF ONCOLOGY (2006)
Colorectal cancer: genetics of development and metastasis
T Takayama et al.
JOURNAL OF GASTROENTEROLOGY (2006)
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
RK Jain et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line
A Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Addition of bevacizurnab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial
FF Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bevacizurnab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
HI Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
DJ Hicklin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
RM Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
F Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Inhibitors of the vascular endothelial growth factor receptor
LS Rosen
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2002)